This involves loading antibodies generated from samples of a patient's unique tumour with PDT dyes to treat the patient.
Not all tumours can be treated by the laser treatment as each type of cancer needs specific drugs with specific dyes and not all have been developed yet.
The National Institute for Health and Clinical Excellence (Nice) has issued guidance on a number of cancers for which PDT can be used.
In the case of non-melanoma skin tumours, Nice said there were 'no major safety concerns' about the treatment.
Guidance on advanced oesophageal cancer meanwhile states: 'Current evidence on the safety and efficacy of palliative photodynamic therapy for advanced oesophageal cancer is of poor quality but appears adequate to support the use of this procedure to relieve symptoms in patients with a poor prognosis.'
Possible complications identified included skin photosensitivity, Nice said.
But people with brain tumours are not recommended to have the procedure unless in the context of trials because of 'limited' evidence on its safety and efficacy, according to Nice guidance.
Source-Medindia
GPL